Form 4: Agios Pharmaceuticals Executive Acquires Stock Options and Restricted Stock Units

Krishnan Viswanadhan, Chief Corp Dev & Strategy at Agios Pharmaceuticals, acquired stock options and restricted stock units on March 5, 2025.

Summary

• Krishnan Viswanadhan, Chief Corp Dev & Strategy at Agios Pharmaceuticals, filed a Form 4 on March 7, 2025, reporting changes in beneficial ownership.
• On March 5, 2025, Viswanadhan acquired 55,374 stock options with an exercise price of $33.95, expiring on March 5, 2035.
• These options vest as to 25% on March 5, 2026, and the remaining 75% vest in 36 equal monthly installments thereafter.
• Viswanadhan also acquired 24,300 restricted stock units on March 5, 2025, which will vest in three equal annual installments beginning on March 5, 2026.
• Each restricted stock unit represents a contingent right to receive one share of Agios Pharmaceuticals' common stock.
• Following these transactions, Viswanadhan directly owns 55,374 stock options and 24,300 restricted stock units.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The grant of stock options and restricted stock units suggests confidence in the company's future, but it's a routine part of executive compensation.

Positives

• The acquisition of stock options and restricted stock units by a key executive could be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The vesting schedules for both the stock options and restricted stock units suggest a multi-year commitment from the executive.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency regarding insider transactions. These filings are closely watched by investors to gauge executive sentiment and potential future performance.

Comparison to Industry Standards

• Stock option and RSU grants are common forms of executive compensation in the pharmaceutical industry.
• Vesting schedules are typically structured to incentivize long-term performance and retention.
• The specific terms of the grants (e.g., vesting schedule, exercise price) would need to be compared to peer companies to assess their competitiveness.

Stakeholder Impact

• The transactions have a potential impact on shareholders through dilution upon exercise of the stock options.
• Employees may view the executive's acquisition of equity as a positive sign of company leadership's commitment.

Key Dates